FDA, Wegovy and Ozempic

Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk's efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to skyrocket in the U.S.
US FDA says lowest dose of Novo Nordisk's weight-loss drug now available
The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's website on Wednesday. Several doses of Novo's GLP-1 therapies such as Wegovy and diabetes drug Ozempic,
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA.
Novo Nordisk’s Ozempic and Wegovy, long in shortage, are now listed as available by FDA
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.
FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able
The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are
Ozempic and Wegovy considered ‘available’ after more than 2 years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA). While the drugs remain on the shortage list for now,
Targeted Oncology7h
FDA Issues Warning on BioZorb Markers After Recall Due to Patient Complications
Providers advised to halt use, monitor patients, and report any complications with BioZorb devices to the FDA.
oncnursingnews8h
October 2024 FDA Approvals for Oncology
October 2024 brought 4 new FDA drug approvals in the oncology space. With new drug regimens in both the solid tumor and blood ...
Monthly Prescribing Reference5h
FDA Accepts Resubmitted Translarna NDA for nmDMD
Ataluren is a protein restoration agent designed to enable the formation of a functioning protein in patients with nonsense mutation.
Managed Healthcare Executive7h
FDA Grants Accelerated Approval of Scemblix for Newly-Diagnosed CML
Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic ...
ALS News Today12h
Neurosense, FDA to meet on Phase 3 plans for PrimeC in ALS
Neurosense Therapeutics will meet with the FDA in early November to discuss plans for a Phase 3 trial to test PrimeC in ALS.
MedPage Today5h
FDA Staff Not Quite Sold on Sotagliflozin for T1D Patients With CKD
Sotagliflozin has faced a difficult path in T1D. The FDA rejected the drug 5 years ago as an adjunct to insulin for adults ...
FDA warns of unlisted steroids in Skin-Cap aerosol cans
The U.S. Food and Drug Administration has warned users of Skin-Cap aerosol spray that there may be undisclosed steroids in the product. According to the FDA, it is marketed to treat many skin ...
Cure Today8h
CAR-T Cell Therapy Receives FDA Designation in Kidney Cancer Subset
Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients ...